Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mette S. van Ramshorst"'
Autor:
Mette S. van Ramshorst, Aafke H. Honkoop, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Caroline M.P.W. Mandigers, Sabine C. Linn, Agnes J. van de Wouw, Gabe S. Sonke, I.A.M. Mandjes, Erik van Werkhoven, Anna van der Voort, Jelle Wesseling, Inge Kemper, Laurence J. C. van Warmerdam, Lidwine W. Tick, Irma M. Oving
Publikováno v:
The Lancet Oncology. 19:1630-1640
Summary Background The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared wi
Autor:
Marie-Jeanne T. F. D. Vrancken Peeters, Emma J. Groen, Mette S. van Ramshorst, Frederieke van Duijnhoven, Ritse M. Mann, Esther H. Lips, Jelle Wesseling, Gabe S. Sonke, Michael Schaapveld, Marieke E. M. van der Noordaa
Publikováno v:
Breast Cancer Research and Treatment, 189, 213-224
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 189, 1, pp. 213-224
Breast Cancer Research and Treatment
Purpose The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for breast-conserving surgery, even in case of excellent treatment response of the invasive componen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf29fcec7f5f5dd928682cd323e1e44
http://hdl.handle.net/2066/238668
http://hdl.handle.net/2066/238668
Autor:
Aafke H. Honkoop, Marie-Jeanne T. F. D. Vrancken Peeters, I.A.M. Mandjes, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Lidwine W. Tick, Anna van der Voort, Inge Kemper, GS Sonke, Sabine C. Linn, Agnes J. van de Wouw, Mette S. van Ramshorst, Laurence J. C. van Warmerdam, Erik van Werkhoven, Jelle Wesseling
Publikováno v:
JAMA Oncology. 7:978
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dualERBB2(formerlyHER2) blockade. Objective To evaluate 3-year event-free survival (EFS
Autor:
Sabine C. Linn, Gabe S. Sonke, I.A.M. Mandjes, Inge Kemper, Carolien H. Smorenburg, Aafke H. Honkoop, Erik van Werkhoven, Jacqueline M. Stouthard, Irma M. Oving, Mette S. van Ramshorst, Vincent O. Dezentjé
Publikováno v:
The Breast. 29:153-159
Background The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive breast cancer. However, increased toxicity has been reported with the addition of pertuzumab, and this ma
Autor:
Gabe S. Sonke, Maartje van Seijen, Mette S. van Ramshorst, Esther H. Lips, Jelle Wesseling, Tessa G Steenbruggen, Liselore Maria Janssen, Erik van Werkhoven, Marie-Jeanne T. F. D. Vrancken Peeters
Publikováno v:
Clinical cancer research, 25(16), 4985-4992. American Association for Cancer Research Inc.
Purpose: In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant therapy improves recurrence-free survival of patients wit
Autor:
Gwen M. H. E. Dackus, Margriet van der Heiden-van der Loo, Mette S. van Ramshorst, Sabine C. Linn, Gabe S. Sonke
Publikováno v:
Breast Cancer Research and Treatment, 158(2), 361. Springer New York
The prognosis of patients with stage II–III Human Epidermal growth factor Receptor 2 (HER2)-positive breast cancer has significantly improved since the addition of trastuzumab to (neo-)adjuvant chemotherapy. Several reports have shown that small (
Autor:
Marleen Kok, Tessa G Steenbruggen, Mette S. van Ramshorst, Carolien H. Smorenburg, Sabine C. Linn, Gabe S. Sonke
Publikováno v:
Drugs, 77(12), 1313. Adis International Ltd
In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a ‘one size fits all’ approach but is curr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75bdf1ade3533d2add5fd6c159857e8
https://dspace.library.uu.nl/handle/1874/355879
https://dspace.library.uu.nl/handle/1874/355879
Autor:
Marie-Jeanne T. F. D. Vrancken Peeters, Jelle Wesseling, Mette S. van Ramshorst, Gabe S. Sonke, Emilie J. Groen, Claudette E. Loo, Gonneke Winter-Warnars, Frederieke van Duijnhoven
Publikováno v:
Breast cancer research and treatment. 164(1)
Neoadjuvant treatment of HER2-positive breast cancer frequently leads to a pathologic complete response (pCR), which is associated with favourable long-term outcome. Treatment regimens typically consist of 6-9 cycles of trastuzumab-based chemotherapy
Autor:
Marie Jeanne T.F.D. Vrancken Peeters, Sjoerd Rodenhuis, Jetske M. Meerum Terwogt, Sabine C. Linn, Monique M.E.M. Bos, Erik van Werkhoven, Jelle Wesseling, Gabe S. Sonke, HM Oosterkamp, Margaret Schot, Mette S. van Ramshorst, I.A.M. Mandjes
Publikováno v:
European Journal of Cancer, 74, 47. Elsevier Limited
European journal of cancer (Oxford, England, 74, 47-54. Elsevier Limited
European journal of cancer (Oxford, England, 74, 47-54. Elsevier Limited
Aim: To determine the efficacy and safety of an anthracycline-free neo-adjuvant regimen consisting of weekly paclitaxel, carboplatin and trastuzumab in HER2-positive breast cancer. Patients and methods: Patients with stage II or III HER2-positive bre